HCPCS Level II code Q9996 designates the subcutaneous injection of ustekinumab-ttwe (Pyzchiva), dosed as 1 mg per unit. As a HCPCS Level II product code for a biologic therapeutic, it matters nationally for billing, supply management, and coverage determinations tied to specialty medications administered in outpatient and ambulatory settings. The code aids payers and providers in identifying the specific biosimilar/therapeutic formulation for claims and utilization tracking.

Key payers included in standard coverage analyses are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ustekinumab-class therapies, typical sites of service for subcutaneous administration, and what the HCPCS code identifies on claims. The publication also outlines common modifiers and administrative considerations associated with HCPCS Level II product codes, and flags where input data was not provided for associated taxonomies, ICD-10 diagnoses, or related codes.

This national-level summary is intended to inform revenue cycle, pharmacy, and clinical teams about the billing identity of Pyzchiva injections, how the code is used on service lines, and the payer landscape relevant to coverage and claim adjudication.